Shake well before using. Topical corticosteroids are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Each mL of Hydrocortisone Lotion USP, 1% and 2��% contains 10 mg and 25 mg respectively of hydrocortisone in a vehicle consisting of carbomer 940, sodium PCA, lactic acid, sodium hydroxide, stearyl alcohol (and) ceteareth-20, glyceryl stearate (and) PEG-100 stearate, cetyl alcohol, isopropyl palmitate, light mineral oil, myristyl lactate, DMDM hydantoin, dehydroacetic acid, fragrance and purified water. Chemically, hydrocortisone is 11, 17, 21-trihydroxypregn-4-ene-3, 20-dione (CHO) and is represented by the following structural formula. Its molecular weight is 362.47 and its CAS Registry Number is 50-23-7. The topical corticosteroids, including hydrocortisone, constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.<br/>Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See Dosage and Administration.) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
2��%���2 fl oz (59 mL) bottle 4 fl oz (118 mL) bottleNDC 59366-2708-2 NDC 59366-2708-4 1%���4 fl oz (118 mL) bottleNDC 59366-2707-4 Store at controlled room temperature, 15��-30��C (59��-86��F).
dailymed-ingredient:DMDM_hydantoin, dailymed-ingredient:PEG-100_stearate, dailymed-ingredient:carbomer_940, dailymed-ingredient:ceteareth-20, dailymed-ingredient:cetyl_alcohol, dailymed-ingredient:dehydroacetic_acid, dailymed-ingredient:fragrance, dailymed-ingredient:glyceryl_stearate, dailymed-ingredient:isopropyl_palmitate, dailymed-ingredient:lactic_acid, dailymed-ingredient:light_mineral_oil, dailymed-ingredient:myristyl_lactate, dailymed-ingredient:sodium_PCA, dailymed-ingredient:sodium_hydroxide, dailymed-ingredient:stearyl_alcohol, dailymed-ingredient:water
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects .
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.